Krystal Biotech, Inc. (NASDAQ: KRYS) is named one of the 10 best NASDAQ growth stocks to buy for the next 10 years. Analysts at Goldman Sachs raise the price target for KRYS from $206 to $327, implying a 16.7% upside. The company is focusing on short-term growth through three registrational programs – KB801, KB803, and KB407, expected to support potential product launches by 2028. Ophthalmic programs are seen as de-risked and scalable, while KB407 is promising in cystic fibrosis. Clear Street and Bank of America also increase price targets, citing growth in Vyjuvek and potential in neurotrophic keratitis market with KB801.

Read more at Yahoo Finance: Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision